Differential role of CD133 and CXCR4 in renal cell carcinoma

Cell Cycle

Volumn 9, Issue 22, 2010, Pages 4492-4500

  D'Alterio, Crescenzo ^a   Cindolo, Luca ^b   Portella, Luigi ^a   Polimeno, Marianeve ^a   Consales, Claudia ^a   Riccio, Anna ^a   Cioffi, Michele ^a   Franco, Renato ^a   Chiodini, Paolo ^c   Cartenì, Giacomo ^d   Mirone, Vincenzo ^d   Longo, Nicola ^d   Marra, Luigi ^a   Perdonà, Sisto ^a   Claudio, Luigi ^a   Mascolo, Massimo ^d   Staibano, Stefania ^d   Falsaperla, Mario ^e   Puglisi, Marco ^e   Martignoni, Guido ^f   Ficarra, Vincenzo ^g   Castello, Giuseppe ^a   Scala, Stefania ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b S Pio da Pietrelcina Hospital   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cancer stem cell; CD133; CXCR4; Prognosis; Renal cell carcinoma

Indexed keywords

CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4;

ADULT; AGED; ARTICLE; CANCER CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION;

EID: 78649864565     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.22.13680     Document Type: Article

References (31)

1. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: A multicenter European study. Cancer 2005; 104:1362-71.
2. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25:1316-22.
3. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007; 57:112-25.
4. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007; 12:1404-15.
5. Linehan WM. Targeting VEGF receptors in kidney cancer. Lancet Oncol 2007; 8:956-7.
6. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006; 11:753-64.
7. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007; 356:185-7.
8. Isbarn H, Karakiewicz PI. Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol 2009; 19:247-57.
9. Gnarra JR, Glenn GM, Latif F, Anglard P, Lerman MI, Zbar B, et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 1993; 20:207-16.
10. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004; 10:6282-9.
11. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10:5464-71.
12. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, et al. Stromal cell-derived factor- 1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: Von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65:6178-88.
13. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 2003; 425:307-11.
14. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 5:56.
15. D'Alterio C, Consales C, Polimeno MN, Franco R, Cindolo L, Portella L, et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 2010; [Epub ahead of print]; DOI: 10.2174/1568210205789900096.
16. Wehler TC, Graf C, Biesterfeld S, Brenner W, Schadt J, Gockel I, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. J Oncol 2008; 626340.
17. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25:977-88.
18. Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: Prominin family gene products in need of a rational nomenclature. Stem Cells 2003; 21:506-8.
19. + renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006; 169:2223-35.
20. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol 2005; 166:545-55.
21. Yanagisawa S, Kadouchi I, Yokomori K, Hirose M, Hakozaki M, Hojo H, et al. Identification and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney. Clin Cancer Res 2009; 15:3014-22.
22. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-23.
23. Wang L, Wang L, Yang B, Yang Q, Qiao S, Wang Y, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis 2009; 26:1049-54.
24. Burger JA, Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23:43-52.
25. Pode-Shakked N, Metsuyanim S, Rom-Gross E, Mor Y, Fridman E, Goldstein I, et al. Developmental tumorigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J Cell Mol Med 2009; 13:1792-808.
26. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 2010; 28:649-60.
27. th Edition. New York NY, USA: Wiley 2002.
28. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumors. J Pathol 1997; 183:131-3.
29. Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 2004; 172:858-62.
30. Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010; 10:218.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-8.